Ablation Therapy or Long-Term Rhythm Medicines: How Cardiologists Weigh the Two Paths

The envelope from the cardiology office contained two things: a printout of a heart tracing with a jagged, uneven stretch circled in pen, and a note that said, simply, “Let’s talk about options.” For the man holding it, a 58-year-old who had spent months feeling his pulse stumble during evening walks, the word that stuck was options. Plural. He had assumed there would be one answer.

There rarely is. For most people with a troublesome heart rhythm, the conversation eventually narrows to two roads. One is a catheter procedure that reaches inside the heart to quiet the tissue misfiring. The other is a daily medicine taken for years to hold the rhythm steady. Weighing ablation vs medication for arrhythmia is one of the more genuinely balanced decisions in modern cardiology, which is exactly why it feels so unsettling from the patient’s chair.

This explainer walks through what each path involves, what the evidence honestly shows, who tends to be steered one way or the other, and the questions worth bringing to the next appointment.

Ablation vs medication for arrhythmia: what the choice is really about

An arrhythmia is any heart rhythm that is too fast, too slow or irregular because the heart’s electrical signals are misfiring. Some are harmless. Others cause palpitations, breathlessness, dizziness, fatigue, or, in the case of atrial fibrillation, raise the risk of stroke. The CDC estimates that atrial fibrillation alone affects millions of adults in the United States, with numbers expected to keep rising as the population ages.

When symptoms interfere with daily life, cardiologists generally think in two layers. The first is protection: preventing strokes and controlling how fast the heart beats. The second is rhythm control, meaning restoring and keeping a normal rhythm. The ablation-or-medication question lives almost entirely in that second layer.

Here is the framing that matters most. Neither path is a one-time fix, and neither is a guarantee. Rhythm medicines, called antiarrhythmics, work only as long as they are taken and only for as long as they keep working, which is not forever for many people. Ablation changes the heart’s wiring physically, but arrhythmias can return, and a second procedure is sometimes needed.

So the real question is not “which one wins?” but “which trade-offs suit this person, this arrhythmia and this heart?” A 40-year-old with intermittent atrial fibrillation and an otherwise normal heart faces a different calculation from an 80-year-old with a stretched, weakened heart and several other diagnoses. The evidence, reviewed in the sections that follow, gives clinicians a map. It does not hand them a single destination.

How does catheter ablation actually work?

Catheter ablation is a procedure in which thin, flexible tubes called catheters are threaded through a blood vessel, usually in the groin, up into the heart. The clinician performing it is typically an electrophysiologist, a cardiologist who specializes in the heart’s electrical system.

Once inside, the team maps the electrical activity, looking for the spot or spots where abnormal signals start or where they loop around. In atrial fibrillation, the culprits are most often where the pulmonary veins enter the left upper chamber, so the tissue around those vein openings is a common target. In other arrhythmias, such as supraventricular tachycardia (a fast rhythm from the upper chambers) or atrial flutter (a rapid, organized circuit), the target may be a single short pathway.

The catheter tip then delivers energy to create tiny scars in that tissue. Scar does not conduct electricity, so the rogue signals are blocked. The energy can be heat from radiofrequency current, extreme cold called cryoablation, or a newer method using very short electrical pulses. Each creates a controlled lesion a few millimeters across.

According to Mayo Clinic, the procedure typically takes about three to six hours, is done under sedation or general anesthesia, and many people go home the same day or after one night. Patients are usually awake enough afterward to hear how it went, though the true verdict on whether the rhythm holds takes months, not hours.

One useful mental image: imagine a fire alarm in an office that keeps triggering because of one faulty sensor. Medication is like lowering the alarm’s sensitivity across the whole building. Ablation is like finding and disconnecting the faulty sensor. Both can quiet the noise. Only one addresses the source directly, and only one carries the risk of cutting the wrong wire.

How do rhythm-control medicines work in the heart?

Antiarrhythmic drugs act on the tiny channels in heart cells that let sodium, potassium and calcium flow in and out. Those ion movements are what generate each electrical impulse. By slowing one channel or another, these medicines make the heart tissue less excitable, lengthen the time cells need before they can fire again, or both. The abnormal circuit finds it harder to start and harder to sustain.

Different classes target different channels, and that is precisely why the choice of drug is so individualized. Sodium-channel blockers tend to be used in people whose hearts are structurally normal. Potassium-channel blockers, including one widely used agent that affects several channels at once, are often chosen when the heart is weakened or enlarged, because they are less likely to provoke dangerous new rhythms in that setting. Beta blockers and calcium-channel blockers, which mainly slow the heart rate rather than restore rhythm, are frequently part of the plan too, sometimes alongside an antiarrhythmic.

Timelines vary with the drug. Some medicines reach steady levels within days; others, particularly the agent with a very long half-life, can take weeks to build up and months to fully leave the body after stopping. The NHS notes that antiarrhythmics can be used either to restore a normal rhythm or to help maintain it after another treatment, and that regular check-ups are part of the deal.

What a medicine cannot do is change the underlying tissue. Stop the tablets and the effect fades. Continue them and the effect may still fade over years as the heart remodels. This is the core reason the medicine path is often described as management rather than repair. Any adjustment to these drugs, including stopping them, belongs with the prescribing clinician, because abrupt changes can themselves trigger rhythm problems.

Is cardiac ablation better than medication? What the trials show

This is the question most people type into a search bar, and the honest answer has two halves.

For keeping people in normal rhythm, randomized trials comparing catheter ablation vs antiarrhythmic drugs have generally favored ablation, particularly in paroxysmal atrial fibrillation, meaning episodes that come and go on their own. People who had ablation were less likely to experience recurrences and more likely to report improved quality of life than those on medicines alone. Several trials in patients who had not yet tried any antiarrhythmic also found ablation as a first step reduced recurrence compared with starting drugs, which is why current guideline language allows ablation to be considered early rather than only after medicines fail. The American Heart Association describes ablation as an option both when medicines have not controlled the rhythm and, for selected patients, as an initial rhythm-control strategy.

For the outcomes patients care about most, such as stroke, death or hospitalization, the picture is more measured. The largest trial to compare the two strategies head to head did not find a statistically significant difference in its main combined outcome of death, disabling stroke, serious bleeding or cardiac arrest, though people assigned to ablation had fewer recurrences and better symptom scores. In the specific group of patients with atrial fibrillation plus heart failure with a weakened pumping function, smaller trials have suggested ablation may reduce hospitalizations and deaths, which is why that group is now often steered toward the procedure.

Put plainly: ablation is better at the job of holding rhythm for many patients. Whether it is better at extending life or preventing stroke for the average person is not established. Anyone told otherwise, in either direction, is hearing something the evidence does not yet support.

Who is ablation usually for, and who is usually asked to wait?

Cardiologists tend to lean toward ablation in a handful of recognizable situations. The clearest is a person with disabling symptoms whose rhythm has not settled on at least one antiarrhythmic, or who could not tolerate the side effects. Another is the younger or middle-aged patient with paroxysmal atrial fibrillation and a structurally normal heart, where trial data on early ablation are strongest and where decades of daily medication is an unattractive alternative. A third is the patient with heart failure and reduced pumping function, for whom the evidence on ablation is more favorable than for the general population.

Certain arrhythmias are almost always steered toward ablation once symptomatic. Typical atrial flutter and most forms of supraventricular tachycardia involve a single, predictable circuit that a catheter can interrupt with a very high likelihood of lasting effect, and both Cleveland Clinic and Johns Hopkins describe these as among the most successful targets.

Who is asked to wait, or to try medicine first? Someone whose episodes are infrequent and mild may reasonably start with a drug or even a “pill in the pocket” approach directed by their clinician. A person with long-standing persistent atrial fibrillation and a badly enlarged left atrium has a lower chance of a durable result, so the team may want to weigh that candidly before committing. Patients with untreated sleep apnea, poorly controlled blood pressure, heavy alcohol use or significant excess weight are often asked to address those drivers first, because they push the arrhythmia to return regardless of the procedure.

Waiting is not the same as being denied. It usually means the team believes the odds improve if some groundwork is laid.

Who should not get a heart ablation?

Few people are told never. More are told not now, or not for this. The distinction matters, so it helps to know the categories.

Some situations make the procedure itself unsafe or impractical in the near term. A blood clot already sitting in the heart’s upper chamber, identified on imaging, generally postpones ablation until it has been treated, because catheters could dislodge it. An active infection, a very recent heart attack or stroke, or a bleeding problem that prevents safe use of blood thinners around the procedure are similar pause buttons. People who cannot lie flat for several hours, or who cannot safely undergo anesthesia because of severe lung or other disease, may need alternatives.

Other situations do not forbid ablation so much as lower its expected benefit. The NHS and Mayo Clinic both note that results are less predictable in long-standing persistent atrial fibrillation and when the atrium is markedly enlarged or scarred. Ablation is also not a treatment for the heart’s tendency to beat too slowly; that is the territory of pacemakers.

A frank word about age. Advanced age by itself is not a contraindication, and many people in their late seventies and eighties undergo ablation. The team weighs frailty, kidney function, other illnesses and what the person actually wants from treatment. Someone with mild symptoms who is comfortable on medicine may sensibly decline a procedure at any age.

Finally, ablation is not appropriate when the goal could be met more simply. If the problem is a fast rate rather than an abnormal rhythm, rate-slowing medicines may be all that is needed. The decision on whether a person is a candidate rests with the electrophysiology team after imaging, blood tests and a detailed history.

What is the downside of heart ablation? Risks in plain language

Any procedure inside the heart carries risk, and honest counseling names them. Most complications are uncommon, and most are treatable, but they are the price of admission that medicine avoids.

The most frequent problems occur at the entry site: bleeding, bruising or damage to the blood vessel in the groin. Less often, the catheter can injure the heart wall, leading to fluid around the heart that may need to be drained. Blood clots can form during the procedure and, rarely, travel to the brain, causing stroke; this is why patients are anticoagulated before, during and after. Mayo Clinic’s list of possible complications also includes damage to heart valves, narrowing of the pulmonary veins, injury to the esophagus (the food pipe, which sits just behind the left atrium), kidney strain from contrast dye, and a new arrhythmia requiring a pacemaker. Death is described as very rare.

Two downsides get less attention. The first is that ablation may not hold. Atrial fibrillation in particular can recur months or years later, and a meaningful share of patients undergo a second procedure. The second is the recovery period itself: a few days of restricted activity, groin soreness, and a stretch of weeks when palpitations may flare while the heart heals, which is disconcerting for someone who hoped to feel instantly better.

Newer energy sources are being adopted partly because they may spare the esophagus and nearby nerves, but longer-term comparative data are still accumulating, and the treating team is the right source for what is available and appropriate.

Weighing afib ablation risks against the burden of years on medicine is legitimately personal. Some people would rather accept a small one-time procedural risk than an indefinite daily obligation. Others feel the reverse. Neither instinct is wrong.

What are the downsides of long-term rhythm medicines?

The medicine road looks gentler at first glance, and for many people it is. Yet antiarrhythmics are among the more demanding drugs in cardiology, and their downsides accumulate over time rather than arriving all at once.

The paradox that clinicians watch for most closely is proarrhythmia: a rhythm medicine causing a new, sometimes dangerous, rhythm disturbance. This is why several of these drugs are started in hospital with continuous monitoring, and why people with structurally abnormal hearts are steered away from certain classes. Regular electrocardiograms to check the heart’s electrical intervals are part of routine follow-up on many agents.

Beyond the heart, side effects depend on the drug. The widely used multi-channel agent can affect the thyroid, liver, lungs, eyes and skin over years of use, which is why blood tests and periodic scans are standard for people taking it. Sodium-channel blockers can cause dizziness, visual disturbance or worsen heart failure in susceptible individuals. Rate-slowing drugs commonly cause fatigue, cold hands or a slow pulse. The NHS and Mayo Clinic both emphasize that these medicines require monitoring and that side effects are a frequent reason people switch or stop.

There is also the quieter cost of adherence. Taking a tablet every day for decades, remembering it while traveling, coordinating it with other prescriptions, and managing interactions with common antibiotics or antifungals is a real burden. Effectiveness fades for some over time as the heart’s tissue changes.

None of this means medicine is the inferior choice. For infrequent episodes, for people with reasons to avoid a procedure, or for those who simply prefer the known to the unknown, drugs remain a sound, guideline-endorsed path. It does mean that “just take a pill” undersells what the pill asks of you.

Ablation vs medication for arrhythmia: a side-by-side view

A table cannot capture an individual’s circumstances, but it can make the shape of the trade-off visible. Everything here reflects general guidance from the sources listed at the end and should be read alongside a clinician’s assessment.

Question	Catheter ablation	Long-term rhythm medicines
What it does	Creates small scars to block abnormal electrical pathways	Alters ion channels so heart tissue is less excitable
Time commitment up front	One procedure of several hours, often same-day or overnight stay	Minutes to start; some drugs begun in hospital with monitoring
Ongoing commitment	Follow-up visits; blood thinners for at least a period; possible repeat procedure	Daily tablets indefinitely; periodic ECGs and blood tests
Main risks	Bleeding, vessel injury, fluid around heart, stroke, esophageal or vein injury (uncommon)	New rhythm disturbances, organ side effects, fatigue, interactions
Rhythm control in trials	Fewer recurrences than drugs in paroxysmal AF and several other arrhythmias	Effective for many; effect fades for some over years
Effect on stroke or survival	Not proven different from drugs in the general AF population; possible benefit in heart failure	Not proven different from ablation
Replaces blood thinners?	No	No
Often preferred when	Symptoms persist despite drugs; younger with normal heart; heart failure with reduced function; flutter or SVT	Episodes infrequent; procedure risk high; patient preference; as first step

Two rows deserve a second look. The stroke-and-survival row is where marketing and evidence most often diverge; the trials simply have not shown that either strategy saves more lives across the board. And the blood-thinner row is a reminder that rhythm control and stroke protection are separate decisions, which the next section takes up.

What the following days and weeks usually look like after ablation

The hours right after the procedure are about the groin. Patients lie flat for a stretch to let the puncture sites seal, then are helped up and watched for bleeding. MedlinePlus and Mayo Clinic describe most people going home the same day or the following morning, with instructions to avoid heavy lifting and strenuous exercise for roughly a week and to keep the entry site clean and dry.

The first few days commonly bring bruising, some soreness, and fatigue. Chest discomfort that is mild and eases with time can occur as the heart tissue heals, and a sore throat is possible if a tube was placed in the esophagus for imaging during the procedure. Most people are back to desk work within days and to ordinary activity within about a week, though the team sets individual limits.

Then comes the part almost nobody expects: the healing window. Cleveland Clinic and other centers describe a period of roughly the first three months, sometimes called the blanking period, during which palpitations and even full episodes of the arrhythmia can recur while inflammation from the lesions settles. These early recurrences do not necessarily mean the ablation failed, and clinicians usually wait until after this window to judge the result. Antiarrhythmic medicines are often continued through it and then reassessed.

Blood thinners are continued for at least a couple of months after atrial fibrillation ablation in essentially all patients, and beyond that according to stroke risk rather than whether the rhythm looks fixed.

Follow-up typically includes a visit in the first weeks, an electrocardiogram, and often some form of longer heart-rhythm monitoring to see what the heart is doing when nobody is watching. Symptom diaries help. So does patience, which is easier when the timeline has been explained in advance.

Why neither path replaces stroke prevention

The most consequential misunderstanding in this whole field is the belief that fixing the rhythm fixes the stroke risk. It does not, at least not in any way the evidence currently allows clinicians to rely on.

Atrial fibrillation raises stroke risk because the upper chambers quiver rather than contract, letting blood pool and clot, most often in a small pouch called the left atrial appendage. A clot that breaks free can travel to the brain. Anticoagulant medicines, commonly called blood thinners, reduce that risk substantially and are recommended based on a person’s overall risk profile: age, blood pressure, diabetes, prior stroke, heart failure, vascular disease and sex.

Here is the key point. Those risk factors do not disappear when the rhythm is controlled. A person may feel entirely normal, have a clean electrocardiogram in the office, and still have brief silent episodes of atrial fibrillation at night. The American Heart Association and the NHS both state clearly that ablation is not a substitute for anticoagulation and that the decision to continue blood thinners after a successful procedure should be based on stroke risk, not on symptoms.

The same is true on the medicine side. An antiarrhythmic that keeps someone in rhythm most of the time does not license stopping anticoagulation. Rhythm drugs and blood thinners are doing two different jobs, and both are usually needed in people with meaningful stroke risk.

For those who cannot take blood thinners because of bleeding, a separate procedure to close off the left atrial appendage exists as an alternative in selected patients. That is a distinct decision with its own evidence base, made with the treating team, and it sits outside the ablation-or-medication question entirely.

What people often get wrong about ablation and rhythm drugs

Some myths are stubborn enough to deserve direct correction.

“Ablation is a permanent fix.” It is a durable treatment for many, particularly for flutter and supraventricular tachycardia, but atrial fibrillation can return, sometimes years later. Repeat procedures are a normal part of the landscape rather than a sign of failure. Both Mayo Clinic and Johns Hopkins note that more than one ablation is sometimes needed.

“Medicines are the safe option and ablation is the risky one.” Ablation carries procedural risk, concentrated in a single day. Antiarrhythmics carry ongoing risk spread across years, including the possibility of provoking new rhythm problems and organ side effects that require monitoring. Safe is relative, and the comparison depends on the individual.

“If I feel fine, I can stop the blood thinner.” Covered above, and worth repeating: stroke protection follows risk factors, not symptoms.

“Ablation is a last resort.” That was the older sequence. Current guideline language allows ablation as a reasonable first rhythm-control choice for selected patients, based on randomized trials of early ablation. Whether it is first or second for a given person is a discussion, not a rule.

“An irregular heartbeat is an irregular heartbeat.” The target matters enormously. A single accessory pathway in supraventricular tachycardia is a very different proposition from diffuse scarring in long-standing atrial fibrillation, and the odds of a lasting result differ accordingly.

“Lifestyle changes are optional once you have a procedure.” Sleep apnea treatment, blood pressure control, moderating alcohol and maintaining a healthy weight all lower recurrence after ablation and improve medicine effectiveness. They are part of the treatment, not a footnote to it.

“Newer always means better.” New energy sources look promising and may reduce certain injuries, but long-term comparative outcomes are still being gathered. Enthusiasm is reasonable; certainty is premature.

Questions to ask your care team before choosing

A good consultation is a conversation, and conversations go better with a list. These questions are drawn from what patients most often wish they had asked, and each has a real answer the team can give.

• Exactly which arrhythmia do I have, and how does that affect the likelihood that ablation would last?
• Based on my heart’s size and function, do you consider me a strong, moderate or weak candidate for ablation, and why?
• If I try medicine first, which class would you consider, what monitoring would it need, and how would we know it was time to reconsider?
• What is my stroke risk, and will I need a blood thinner regardless of which path we choose?
• Which energy source would you use for ablation, and what are its particular risks for someone like me?
• How many procedures like mine does your center perform, and how are complications tracked and reviewed?
• What does the first three months after ablation look like, and what symptoms should I expect versus report?
• If the arrhythmia comes back after ablation, what would the next step be?
• Are there conditions I should treat first, such as sleep apnea or blood pressure, that would improve my odds on either path?
• How will this choice affect my ability to work, drive, travel or exercise in the near term?
• If I do nothing beyond rate control and stroke prevention for now, what are the risks of waiting?

Bringing someone along to take notes helps. So does asking the team to write down the key numbers they quote, so they can be revisited at home. A decision this balanced deserves a second visit if the first one leaves questions unanswered, and most clinicians welcome that request.

When to call your doctor: red-flag signs on either path

Whichever road a person takes, some symptoms should prompt a same-day call to the care team, and a few should prompt emergency services.

Call emergency services immediately for chest pain or pressure that does not ease, sudden severe shortness of breath, fainting or near-fainting, or any sign of stroke: sudden weakness or numbness on one side of the body, facial drooping, trouble speaking or understanding, sudden confusion, or sudden loss of vision. These apply whether the person is on medicine, recently had ablation, or has done neither.

After ablation, contact the team promptly for bleeding from the groin site that does not stop with firm pressure, a rapidly growing lump or severe pain at the site, a leg that becomes cold, pale, numb or very painful, fever or chills, chest pain that worsens when lying flat or breathing in, difficulty or pain when swallowing, or coughing up blood. Mayo Clinic and MedlinePlus list these as reasons to seek care without delay.

On rhythm medicines, report a heartbeat that feels much faster or more irregular than usual, a pulse that has become very slow, new dizziness or blackouts, unusual shortness of breath, a persistent dry cough, yellowing of the skin or eyes, visual changes, or new sensitivity to sunlight. Some of these can signal the medicine is affecting the rhythm or another organ, and the prescriber will decide whether tests or adjustments are needed. Do not stop or change the dose on your own; abrupt changes can themselves provoke arrhythmias.

Palpitations that come and go without other symptoms, especially in the weeks after ablation, are usually worth logging and mentioning at the next visit rather than a reason for alarm. When unsure, calling is always the right choice; care teams would far rather hear about a false alarm than miss a real one.

Frequently asked questions

Is cardiac ablation better than medication?

For keeping the heart in normal rhythm, ablation has outperformed antiarrhythmic drugs in randomized trials, particularly for paroxysmal atrial fibrillation and for flutter or supraventricular tachycardia. For preventing death or stroke in the general population, the largest trial found no significant difference between the two strategies. Better therefore depends on which outcome matters most to you and on your arrhythmia type, heart structure and other conditions, which your cardiologist will weigh with you.

What is the downside of heart ablation?

The main downsides are procedural risks and the chance the arrhythmia returns. Uncommon complications include bleeding or vessel injury at the groin, fluid around the heart, stroke, damage to the esophagus or pulmonary veins, and a new rhythm problem needing a pacemaker. Recovery involves days of restricted activity and weeks when palpitations may flare while tissue heals. Atrial fibrillation in particular can recur, and some people need a second procedure.

Who should not get a heart ablation?

Ablation is usually postponed or avoided when a clot is present in the heart, during active infection, soon after a heart attack or stroke, or when bleeding problems prevent safe anticoagulation. It offers less benefit in long-standing persistent atrial fibrillation with a markedly enlarged atrium, and it does not treat slow heart rhythms. Age alone is not a barrier; frailty, other illnesses and personal goals guide the team’s decision.

What is the best medication for an irregular heartbeat?

There is no single best medicine, because the right drug depends on the type of arrhythmia, whether the heart is structurally normal, kidney and liver function, and other medicines being taken. Sodium-channel blockers are often used in structurally normal hearts, while certain potassium-channel blockers are preferred when the heart is weakened. Rate-slowing drugs such as beta blockers may be used alone or alongside. Only the prescribing clinician can determine what suits an individual.

How do catheter ablation vs antiarrhythmic drugs compare for long-term quality of life?

Trials that measured quality of life generally found larger improvements with ablation than with drugs, mainly because people had fewer symptomatic episodes and avoided medicine side effects. The difference was most pronounced in patients with troublesome symptoms before treatment. People with mild, infrequent episodes may see little difference either way. Quality-of-life gains from ablation also depend on the rhythm holding, which is why follow-up beyond the first year matters.

What are the main afib ablation risks I should weigh?

The risks most often discussed are bleeding or vessel damage at the catheter entry site, fluid collecting around the heart, stroke from a clot dislodged during the procedure, injury to the esophagus behind the left atrium, narrowing of the pulmonary veins, kidney strain from contrast dye, and the rare need for a pacemaker. Death is very rare. Your team can share how these risks apply to your heart and their own tracked outcomes.

Can I stop my blood thinner if the ablation works?

Not on the basis of a successful ablation alone. Stroke risk in atrial fibrillation depends on factors such as age, blood pressure, diabetes, heart failure and prior stroke, and those do not change when the rhythm is corrected. Brief silent episodes can also go unnoticed. Guidelines advise continuing anticoagulation for at least a period after ablation in everyone, and long term according to stroke risk. This decision belongs with your cardiologist.

How long does it take to know if ablation worked?

Clinicians usually wait until after a healing window of roughly three months, often called the blanking period, before judging the result. During that time the lesions are settling and palpitations or even full episodes can occur without meaning the procedure failed. Follow-up typically includes an electrocardiogram and often longer rhythm monitoring to capture what happens between visits. A true assessment of durability comes over the following year or more.

Can I try medication first and have ablation later?

Yes, and this remains a common and reasonable sequence. Many people start with an antiarrhythmic and move to ablation if the drug fails to control symptoms or causes side effects. The main caution is that the longer atrial fibrillation persists, the more the atrium can remodel, which may reduce the chance of a lasting result later. Your team can advise whether waiting carries meaningful cost in your case.

Is ablation better than medication for older adults?

Age by itself does not decide this. Older adults are represented in the major trials, and many undergo ablation safely, but frailty, kidney function, bleeding risk and other illnesses shift the balance. Someone in their eighties with mild symptoms who tolerates a medicine may sensibly stay on it; another with disabling episodes and a strong heart may benefit from ablation. The treating team assesses the individual rather than the birth year.

References

• NHS: Atrial fibrillation, treatment
• MedlinePlus: Cardiac ablation procedures
• Cleveland Clinic: Catheter ablation
• CDC: About atrial fibrillation

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.